We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SDI Announces Participation of Berlex in Its Genomic Antibodies™ Initiative
News

SDI Announces Participation of Berlex in Its Genomic Antibodies™ Initiative

SDI Announces Participation of Berlex in Its Genomic Antibodies™ Initiative
News

SDI Announces Participation of Berlex in Its Genomic Antibodies™ Initiative

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SDI Announces Participation of Berlex in Its Genomic Antibodies™ Initiative "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Strategic Diagnostics Inc. has announced that Berlex Inc., a U.S. affiliate of Schering AG, Germany, has extended its Services Agreement to include SDI's commercialized Genomic Antibodies™ offering.

Under terms of this amended agreement, SDI will provide polyclonal and monoclonal Genomic Antibodies™ to Berlex.

Matthew H. Knight, President and CEO of Strategic Diagnostics commented, "We are extremely pleased to have a world-class company recognize the utility of Genomic Antibodies™."

"The SDI Genomic Antibodies™ process significantly reduces the time required to produce a custom antibody for Berlex and Genomic Antibodies™ are successfully produced to traditionally difficult antigen targets such as transmembrane proteins, membrane-associated proteins and highly conserved proteins, which will help Berlex to identify and market new pharmaceuticals more quickly."

Mr. Knight continued, "We are just beginning our commercial efforts for this exciting new offering and continue to interact with a number of significant companies and research initiatives."

"We believe we bring significant value to our customers by decreasing the time to deliver new diagnostics and or therapeutics to the market."

Advertisement